Oral Pyrophosphate Absorption in PXE Disease

• Status: Withdrawn
• Trial end date: 2021-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification. The aim of our study is to find optimal dosing and safety of oral disodium-PPi (Na2H2PPi). Absorption curves (pharmacokinetics), AUC0-t, Cmax and Tmax for PPi and phosphate will be provided for healthy controls and PXE-patients both fasting and with standard meal intake.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tampere University Hospital
• Collaborators: Hungarian Academy of Sciences; UMC Utrecht

Criteria

Inclusion Criteria:

• Adults (>18 yrs)

• clinically and genetically proven PXE

• Body mass index (BMI) 18,5-34,9 kg/m2

Exclusion Criteria:

• Special groups according to researchers' decision.

• Pregnancy

• No effective contraception in females in child-bearing age.